Press Releases

 
Press Releases
  Date Title View
May 17, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The UBS 2016 Global Healthcare Conference on May 24, 2016 at 8:00 a.m. EDT in N...
May 5, 2016
Conference Call Scheduled Today at 8:30 a.m. EDT LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2016. "We are continuing to build a diverse pipeline based on our deuterium ...
May 4, 2016
Phase 1 to Begin Second Quarter of 2016 Conference Call Scheduled Tomorrow at 8:30 a.m. EDT for Company Update and First Quarter 2016 Financial Results LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced its next ...
Apr 28, 2016
Multiple Dose Data Continues to Support Once-Daily Dosing and Differentiated Metabolite Profile Data to be Presented at the European Cystic Fibrosis Conference in June 2016 LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) toda...
Apr 28, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2016 financial results on Thursday, May 5, 2016, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. EDT to discuss f...
Apr 14, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Christine van Heek has been appointed to its Board of Directors and will serve as a member of its audit committee effective April 8, 2016. Ms. van Heek has more than 30 years of experience in the healthc...
Mar 23, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Meghan FitzGerald has been appointed to its Board of Directors and will serve as a member of its compensation committee effective March 22, 2016. "We are delighted to welcome Meg to our B...
Mar 1, 2016
- Focus on Clinical Program Advancement in 2016 - - CTP-656 Solid Dose Phase 1 Results Confirmed Superior Pharmacokinetic Profile to Kalydeco® - - Conference Call Scheduled Today at 8:30 a.m. ET - LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert ...
Feb 29, 2016
Conference Call Scheduled Tomorrow at 8:30 a.m. ET LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced new results from Part 1 of its multiple ascending dose Phase 1 clinical trial in which a single-dose tablet formulation of CTP-656 was ...
Feb 29, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The 36th Annual Cowen and Company Healthcare Conference on March 7, 2016 at 2:0...
FirstPrevious
3
...
NextLast
= add release to Briefcase